FinnCap Reaffirms “Corporate” Rating for Premaitha Health PLC (NIPT)

Premaitha Health PLC (LON:NIPT)‘s stock had its “corporate” rating reissued by FinnCap in a research report issued to clients and investors on Monday.

Premaitha Health (LON NIPT) opened at GBX 5.30 ($0.07) on Monday. Premaitha Health has a 1-year low of GBX 4.05 ($0.05) and a 1-year high of GBX 14.40 ($0.19).

TRADEMARK VIOLATION NOTICE: “FinnCap Reaffirms “Corporate” Rating for Premaitha Health PLC (NIPT)” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at

Premaitha Health Company Profile

Premaitha Health PLC is engaged in molecular diagnostics business for research into, and the development and commercialization of gene analysis techniques for pre-natal screening and other clinical applications in the early detection, monitoring and treatment of disease. The Company’s product, the IONA test is a non-invasive in vitro diagnostic product for prenatal screening enabling clinical laboratories to offer a regulated non-invasive prenatal test in-house.

Receive News & Ratings for Premaitha Health PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Premaitha Health PLC and related companies with's FREE daily email newsletter.

Leave a Reply